AQP4 and neuromyelitis optica: While one study suggested that clinical benefit may relate to a decline in anti-AQP-4 antibody titers [4], it is unclear whether depletion of CD20+ AQP4-specific plasma cell precursors provides the sole and entire basis for therapeutic benefit of anti-CD20 in NMO [6].